Compare Grab Holdings Ltd. (GRAB) vs Hims and Hers Health Inc (HIMS) Price & Performance

GRAB trades at $3.715, down 2.24% today, with a bullish technical signal from moving averages. The company achieved profitability in 2025 with $268M net income and 7.95% margin, showing significant improvement from previous losses. Revenue grew to $3.37B in 2025, with strong analyst consensus of 11 buys versus 1 sell. Recent news includes CEO share sales and Uber CEO's board departure, creating some investor uncertainty despite positive earnings beats.

GRAB presents a compelling turnaround story with recent profitability and strong growth prospects in Southeast Asian markets. The stock trades at a discount to the $5.45 consensus target, offering 47% upside potential. Key risks include competitive pressures, execution challenges in expanding financial services, and insider selling activity. The company's improving cash flow and debt management support the bullish analyst outlook.

Hims & Hers Health trades at $34.78, down 1.05% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company reported $2.35B revenue in 2025 but faces profitability challenges with a negative net income margin of -0.56% and elevated valuation ratios including a P/E of 57.14. Recent news highlights expansion in weight-loss therapies and international markets, with Q2 2026 earnings due August 10, 2026.

The outlook remains cautiously optimistic with analyst consensus at Buy (35%) and a $33.57 price target near current levels. Key opportunities include GLP-1 therapy growth and subscriber additions, while risks involve profitability pressures, competitive threats, and reliance on regulatory approvals. The stock's performance hinges on execution in high-margin segments and cost management amid expansion.